Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovadicitinib in moderate to severe chronic graft-versus-host disease
NCT06682169Phase 3Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2024
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rovadicitinib in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Objective Remission Rate at 24 weeks. Started Nov 2024; status: recruiting.
02
Drugs
rovadicitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06682169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682169.